Optiscan Imaging Limited (ASX:OIL) reports that its innovative ViewnVivo system has been installed for evaluation at Stanford University in the US.
ViewnVivo is Optiscan’s endomicroscope system for Preclinical Research that promises to revolutionise microscopic biological imaging. It allows preclinical researchers to obtain cellular and sub-cellular images from living tissue in a living animal (in vivo) in real time.
It also provides greater control and flexibility – as the researcher can take the imaging to the model rather than adapt the model for imaging – and provides images of significantly higher resolution compared to other existing endomicroscope technologies.
Optiscan Chief Executive Officer Archie Fraser, said Stanford University is one of the world’s leading research universities, located in California’s Bay Area. It currently has 7,032 undergraduates and 9,304 graduates, while its research budget is $US1.6 billion. The University currently has more than 6,000 externally sponsored research projects.
The University selected the ViewnVivo system for evaluation after seeing the system in action at the World Molecular Imaging Congress (WIMC) in Philadelphia in September 2017. It is using ViewnVivo to understand the complexities of biological systems in vivo through the use of specific fluorescent dyes.”
A successful evaluation, being conducted under agreed success criteria, could lead to a potential sale to the University and Optiscan’s exclusive North America distribution partner is currently progressing discussions on this matter.
“The installation, demonstration and evaluation of ViewnVivo at Stanford shows the increasing acceptance of our innovative system by the global Preclinical Research community,” Mr Fraser said.
“We are honoured that a University of Stanford’s calibre has selected our platform, particularly as they are very aware of other existing microscopic imaging technologies. This is a significant validation of the ViewnVivo offering,” Mr Fraser said.
